Clock Ticks On Adding OTC Monograph Reform To FDA User Fees Bill
This article was originally published in The Pink Sheet
Executive Summary
With Congress leaving Washington for Independence Day week and much of August, few days remain to consider adding to each chamber's reauthorization legislation language from Sens. Isakson and Casey's discussion draft for US OTC monograph reform and a user fee program to support FDA's work.
You may also be interested in...
Drug Pricing Hearing In Senate Postponed, Handing Innovators Another Victory
First hearing in Sen. Alexander's committee was dominated by Democrat complaints about Obamacare repeal; now that there's an actual bill to criticize, the next one might have been even worse, but regardless of the reason, the postponement means innovator prices get to stay out of the spotlight once again.
OTC Monograph Reform Proposal Offers Two-Tier Approach
One tier could provide two-year exclusivity, should FDA request clinical trials for new conditions or ingredients, under a US Senate discussion draft. Essentially stalled monograph process would be replaced by deadlines for FDA action in under two years.
OTC Monograph User Fees Up To $34M Floated In Senate Discussion Draft
Bulk of user fees would be raised through facility fees, under Sens. Isakson and Casey’s discussion draft, but there's little time to add the changes to FDA user fee reauthorization bills already moving in Congress.